Adjuvant Therapy of Ensartinib in Stage IB-IIIA ALK-positive Non-small Cell Lung Cancer
This is a prospective, multi-center, single-arm, phase 2 study aiming to assess the efficacy and safety of adjuvant use of Ensartinib in stage IB-IIIA non-small cell lung cancer (NSCLC) with positive ALK-fusion. Enrolled patients will take Ensatinib for 3 years or until recurrence of the disease or intolerable toxicity, following complete tumour resection with or without adjuvant standard chemotherapy.
Non-small Cell Lung Cancer
DRUG: Ensartinib
3-year disease free survival rate (DFSR), Defined as the percentage of patients alive and disease free at 3 years, 3 years
5-year overall survival rate, Defined as the percentage of patients alive at 5 years, 5 years|disease free survival (DFS), Defined as the time from the date of starting treatment until the date of disease recurrence or death (by any cause in the absence of recurrence), Up to 5 years|overall survival (OS), Defined as the time from starting treatment to death., Up to 5 years|Adverse Events, The safety and tolerability profile of Ensartinib, Up to 3 years
This is a prospective, multi-center, single-arm, phase 2 study aiming to assess the efficacy and safety of adjuvant use of Ensartinib in stage IB-IIIA non-small cell lung cancer (NSCLC) with positive ALK-fusion. Enrolled patients will take Ensatinib for 3 years or until recurrence of the disease or intolerable toxicity, following complete tumour resection with or without adjuvant standard chemotherapy.